Drug Trial Radar · NCT04180215
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Dec 11, 2019
Primary completion
Jan 9, 2025
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Hookipa Biotech GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
Conditions
- HPV-Related Squamous Cell Carcinoma
Interventions
HB-201 intravenous administration.Drug
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
HB-202 intravenous administration alternating with HB-201 intravenous administration.Drug
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
HB-201 intravenous administration + standard of care regimen including pembrolizumab.Drug
Dose Expansion
HB-202 / HB-201 alternating intravenous administration + pembrolizumab.Drug
Dose Expansion
HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.Drug
Dose Expansion
HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)Drug
Dose escalation; 10 patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I Dose Escalation: Determine Phase II dose based on incidence of dose-limiting toxicities.Time frame: From dosing until 21-28 days after first dose
- Phase II Dose Expansion: Number of participants with preliminary antitumor activity based on objective response rate.Time frame: Until progression, (estimated up to 30-months)
Locations
34 sites in 3 countries. Site status is shown where the registry gives one.
O'Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office
Fayetteville, Arkansas
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UCLA (University of California, Los Angeles)
Los Angeles, California
Sylvester Comprehensive Cancer Center
Miami, Florida
University of Chicago Medical Center
Chicago, Illinois
Loyola University Medical School
Maywood, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
University of Kansas Medical Center
Fairway, Kansas
Henry Ford Hospital
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Grossman School of Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Perlmutter Cancer Center at NYU Langone Hospital-Long Island
New York, New York
Montefiore-Einstein Center for Cancer Care
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Providence Portland Medical Center
Portland, Oregon
Greenville Hospital System University Medical Center (ITOR)
Greenville, South Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virgina Health System
Charlottesville, Virginia
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin
Amsterdam UMC, Locatie VUMC
Amsterdam, Netherlands
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.